Clinical trial
BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
NCT00039156 · Theradex, Industry · Unknown status
Key facts
| NCT number | NCT00039156 |
|---|---|
| Title | BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma |
| Official title | An Open Phase II Multi-Center Trial of BAY 59-8862 in Patients With Aggressive Refractory Non-Hodgkin's Lymphoma |
| Lead sponsor | Theradex, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | ortataxel |
| Start date | Jan 1, 2002 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 24, 2008 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: